MARKET WIREMoomoo • 6h ago
ALX Oncology(ALXO) Stock Options Chain | Quotes & NewsMoomoo report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.
Why ALXO Stock Traded Steady Today — RQD Quant Desk Flash
$1.22 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.22
ALX Oncology Holdings Inc. (ALXO) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $152.4M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ALXO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ALXO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, ALX Oncology Holdings Inc. (NASDAQ: ALXO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $1.22 (0.00% 1D, market cap $152.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ALXO ranks #296 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ALXO compare to DERM and MGNX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALXO carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DERM (Journey Medical Corporation) holds a E grade (31/100 RQD, P/E N/A, ROIC -19.5%, cap $152.7M) and MGNX (MacroGenics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $151.6M). Among the 5-stock peer group, ALXO leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ALXO?
▼
Per ALXO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001810182), ALX Oncology Holdings Inc. generated $0 in revenue, -$101.7M in net income, and -$84.4M in free cash flow against $59.0M in total assets and $4.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.22 (-0.19%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-3.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALXO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (50/100 Composite)
🔍 WHY ALXO SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (26% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (24% of score)
FRED Regime × Technicals: 20% of 52W Range • RSI-14 at 47.4 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution7/20 pts (-13 pt drag)
Disciplined Float (+0.16% YoY Shares) & executive Form 4 sales trim 13 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$1.25-15.2% Next Q
58
Q2 (-2Q)Grade C$1.06+10.4% Next Q
55
Q3 (-1Q)Grade C-$1.17+4.3% Next Q
53
CurrentGrade D$1.22-1.4% Hist 90D α
50
Trajectory: C (58) → D (50)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ALXO Turnaround Squeeze
While ALXO currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.51) and Max Pain ($1.28) forces dealer call-delta covering toward $2.79.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALXO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ALXO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ALXO Stock Traded Steady Today — RQD Quant Desk Flash
ALX Oncology Holdings Inc. (ALXO) slipped 0.00% to $1.22, trading at 20% of its 52-week range ($0.86 – $2.66). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 20% of its 52-week range ($0.86 – $2.66) with RSI-14 at 47.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.22 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ALXO Headlines & Catalysts
MARKET WIREThe Globe and Mail • 9h ago
Wells Fargo Remains a Buy on ALX Oncology Holdings (ALXO)The Globe and Mail report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 12h ago
ALX Oncology Exchanges 13.35M Shares for Pre-Funded Warrants With Key HoldersTradingView report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance Singapore • 15h ago
Coherus Oncology, Inc. (CHRS) stock price, news, quote and historyYahoo Finance Singapore report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 18h ago
12 Health Care Stocks Moving In Friday's Intraday Session - Marker Therapeutics (NASDAQ:MRKR), Alaunos ThBenzinga report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 21h ago
ALXO Q3'26 Earnings: revenue estimate is 0 USDTradingView report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance Singapore • 1d ago
Acumen Pharmaceuticals, Inc. (ABOS) stock price, news, quote and historyYahoo Finance Singapore report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREwww.dars.gov.et • 1d ago
ALX Oncology (ALXO) Rises 6% to $1.06 as Clinical-Stage Biotech Presses Toward Resistance - Key Reversal Daywww.dars.gov.et report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 17d ago
12 Health Care Stocks Moving In Friday's Intraday SessionGainers Marker Therapeutics (NASDAQ:MRKR) stock increased by 21.2% to $1.11 during Friday's regular session. The market value of their outstanding shares is at $14.8 million. Alaunos Therapeutics (NASDAQ:TCRT)
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALXO)
- ✓Walkthrough of ALXO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ALXO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.24%▼ DESCENDING CHANNEL
2026-10-30O $1.20H $1.26L $1.20C $1.22VOL 421.0K
RES: $1.75SUP: $0.79SMA50: $1.51SMA200: $1.82
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ALXO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ALXO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ALXO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ALXO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALXO)
Health Care Rank #296 of 1016
⚔️ DERM vs ALXO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ALXO vs. DERM, MGNX, NGEN, CUE)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, ALX Oncology Holdings Inc. (ALXO) ranks #296 by composite RQD confidence (50/100, grade D) and #607 by equity capitalization ($152.4M). Within this direct 5-issuer industry benchmark cohort, ALXO leads on earnings valuation at N/A trailing P/E, while DERM leads on capital efficiency and profitability with -19.5% ROIC and 65.8% gross margin. ALXO currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ALXO
ACTIVE
ALX Oncology Holdings Inc. | D | 50/100 | — | — | -35.0% | 0.00% | $152.4M | Benchmark Subject |
| DERM Journey Medical Corporation | E | 31/100 | — | 65.8% | -19.5% | -4.44% | $152.7M | /derm-vs-alxo → |
| MGNX MacroGenics Inc. | E | 31/100 | — | 96.0% | -35.0% | +0.84% | $151.6M | /mgnx-vs-alxo → |
| NGEN NervGen Pharma Corp. | D | 49/100 | — | — | — | -4.86% | $155.0M | /ngen-vs-alxo → |
| CUE Cue Biopharma Inc. | E | 33/100 | — | — | -35.0% | -2.70% | $155.8M | /cue-vs-alxo → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001810182In its most recent audited fiscal period (FY2025, filed 2025-12-31), ALX Oncology Holdings Inc. (ALXO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$101.7M, operating cash flow of -$84.1M, and free cash flow of -$84.4M (+31.1% YoY). On the balance sheet, ALXO closed FY2025 with $59.0M in total assets against $4.5M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$101.7M | -$84.1M | -$84.4M | $59.0M | $4.5M |
| FY2024 (FY) | 2024-12-31 | $0 | -$134.8M | -$121.9M | -$122.4M | $147.8M | $9.5M |
| FY2023 (FY) | 2023-12-31 | $0 | -$160.8M | -$130.4M | -$130.4M | — | — |
3. ALXO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ALXO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, ALX Oncology Holdings Inc. (NASDAQ: ALXO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $1.22 (0.00% 1D, market cap $152.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ALXO ranks #296 in composite RQD confidence.
How does ALXO compare to DERM and MGNX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALXO carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DERM (Journey Medical Corporation) holds a E grade (31/100 RQD, P/E N/A, ROIC -19.5%, cap $152.7M) and MGNX (MacroGenics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $151.6M). Among the 5-stock peer group, ALXO leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ALXO?
Per ALXO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001810182), ALX Oncology Holdings Inc. generated $0 in revenue, -$101.7M in net income, and -$84.4M in free cash flow against $59.0M in total assets and $4.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ALXO trading relative to its 50-day, 200-day, and 52-week technical levels?
ALXO last traded at $1.22 (0.00% on volume of 422,213 shares), positioning the stock -19.21% below its 50-day simple moving average ($1.51) and -32.97% below its 200-day simple moving average ($1.82). Across its 52-week range of $0.86 to $2.66, ALXO sits at the 20.0% percentile with a 14-day RSI of 47.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.07 to $1.37).
ALXO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ALXO stock moving today?
Why ALXO Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 50/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ALXO — ALX Oncology Holdings Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:42:31Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ALXO scores 50 out of 100, a D grade labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC of -35%; FCF yield of 0%), Whale/13F Flow at 10/20 (institutional accumulation and options positioning), Insider Conviction at 7/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 12/20 (beta of 1.0; sector sensitivity), and Forensic Balance Sheet at 13/20 (Altman Z of 2.5; Piotroski F of 4/9; Debt/Equity of 0.17).
For a prospective investor, the weakest pillar is the cash engine: the rating reflects a return on invested capital of -35% and no free-cash-flow yield, meaning the business is consuming capital rather than generating it. The balance sheet pillar is the relative strength, with a Debt/Equity of 0.17 and an Altman Z of 2.5, but a Piotroski score of 4/9 signals only middling financial quality. Insider and institutional pillars sit in the lower-middle range, suggesting limited conviction signals in either direction. Upside, if it exists, would depend on a change in the cash-burn trajectory that the source data does not show; valuation cannot be assessed on earnings because no earnings multiples are available in the source data. This brief is educational and not personalized advice.
Business
Per the Profile section, ALX Oncology Holdings Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Products, customers, and revenue model are not described in the source data. Reported revenue across the financial periods provided is $0.0M in each year, consistent with a pre-revenue profile, but the source data does not describe the commercial pathway.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-104.0M | $-101.7M | N/A | $-84.4M | $16.4M | $4.5M |
| FY 2024 | $0.0M | $-142.5M | $-134.8M | N/A | $-122.4M | $17.6M | $9.5M |
| FY 2023 | $0.0M | $-170.3M | $-160.8M | N/A | $-130.4M | N/A | N/A |
Per the SEC financials, operating losses narrowed from $-170.3M (FY 2023) to $-104.0M (FY 2025), and free-cash-flow burn declined from $-130.4M to $-84.4M over the same window. Gross, operating, and net margins are each reported as 0%, and ROIC is -35%. The per-the-Roarable-RQD forensic readings are an Altman Z of 2.5, a Piotroski F of 4/9, and a Debt/Equity of 0.17. Cash of $16.4M in FY 2025 is small relative to the reported annual cash burn, a tension the source data does not resolve.
Recent Catalysts & News Wire Analysis
The news wire contains six items, all tagged to ALXO with a YELLOW signal light. Headlines reference a Wells Fargo "buy" commentary, an exchange of 13.35M shares for pre-funded warrants with key holders, a Q3'26 earnings entry showing a revenue estimate of 0 USD, and several market-movement and quote-page items. The share-exchange headline is the most substantive catalyst, as it concerns share-count and dilution mechanics; the source data does not provide the terms, pricing, or resulting share count. Per the Butterfly Supply-Chain Graph, no proprietary signals are recorded for the issuer.
Open Questions
- What is the company's pipeline and revenue pathway, given $0.0M reported revenue across all periods?
- What are the terms and resulting share count of the 13.35M-share pre-funded warrant exchange?
- What is the cash runway, given FY 2025 cash of $16.4M against FY 2025 free-cash-flow burn of $-84.4M?
- Why is FY 2023 cash and debt not reported in the source data?
- What are the forward earnings or valuation expectations, given that no P/E or EV/EBITDA figures are available?
ALXO Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for ALX Oncology Holdings Inc. (ALXO) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Moomoo • 6h ago
ALX Oncology(ALXO) Stock Options Chain | Quotes & News Moomoo report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 9h ago
Wells Fargo Remains a Buy on ALX Oncology Holdings (ALXO) The Globe and Mail report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 12h ago
ALX Oncology Exchanges 13.35M Shares for Pre-Funded Warrants With Key Holders TradingView report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance Singapore • 15h ago
Coherus Oncology, Inc. (CHRS) stock price, news, quote and history Yahoo Finance Singapore report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 18h ago
12 Health Care Stocks Moving In Friday's Intraday Session - Marker Therapeutics (NASDAQ:MRKR), Alaunos Th Benzinga report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 21h ago
ALXO Q3'26 Earnings: revenue estimate is 0 USD TradingView report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance Singapore • 1d ago
Acumen Pharmaceuticals, Inc. (ABOS) stock price, news, quote and history Yahoo Finance Singapore report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.dars.gov.et • 1d ago
ALX Oncology (ALXO) Rises 6% to $1.06 as Clinical-Stage Biotech Presses Toward Resistance - Key Reversal Day www.dars.gov.et report covering ALX Oncology Holdings Inc. (ALXO) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ALXO Bull vs. Bear Conversation Board — What's Your Call at $1.22?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALXO 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $1.32 (+8.2%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ALXO (D • RQD 50/100) a Buy at $1.22?
Welcome to the ALXO (ALX Oncology Holdings Inc.) Roar Pit. Current RQD Composite is 50/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $0.99 (-18.9%)
Spot @ $1.22 Pump the brakes on ALXO — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ALXO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless ALX Oncology Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH
🎯 Target: $1.43 (+17.2%)
Spot @ $1.22 ALXO cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ALXO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.22 (52-wk range $0.86 - $2.66), any beat on forward guidance forces shorts and underweight funds to chase.